Financial Report: Merck

Merck
2Q Revenues: $ $10.5 billion (+5%)
2Q Earnings: $1.7 billion (-12%)
YTD Revenues: $20.5 billion (+6%)
YTD Earnings: $2.5 billion (-30%)
Comments: Pharmaceutical sales increased 6% in the quarter to $9.3 billion, driven by growth in oncology, vaccines and hospital acute care, partially offset by lower sales in virology and the ongoing impacts of the loss of market exclusivity for several products. KEYTRUDA sales were up 89% to $1.7 billion. JANUVIA sales were $1.5 billion, up 2%. GARDASIL sales were $608 million, up 30%. PROQUAD, M-M-R II and VARIVAX sales were up 7% to $426 million.  BRIDION sales were up 48% to $240 million. ZETIA / VYTORIN sales were down 31% to $381 million.